Sulindac and its derivatives: A novel class of anticancer agents

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 677-683

  Haanen, C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis modulator; Apoptosis stimulator; Aptosyn; CP 248; CP 461; Exisulind; FGN 1; Neoplasm; NSAID; PDE modulator; Sulindac; Sulindac sulfide; Sulindac sulfone

Indexed keywords

ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CASPASE; CISPLATIN; CP 248; CP 461; CYCLIC AMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP PHOSPHODIESTERASE; CYCLIN DEPENDENT KINASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOCETAXEL; GUANOSINE TRIPHOSPHATE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F1 ALPHA; PROSTAGLANDIN SYNTHASE; SPHINGOMYELIN PHOSPHODIESTERASE; SULINDAC; SULINDAC SULFONE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PARAMETERS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME DEGRADATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; IC 50; INHIBITION KINETICS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; SULINDAC;

EID: 0034980582     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Indomethacin and ascorbate inhibit desmoid tumors
2. Sulindac for polyposis of the colon
3. Sulindac treatment for familial polyposis coli
4. Prostaglandin synthesis inhibition: Effect on bone changes and sarcoma tumor induction in BALB/c mice
5. Mechanism of inhibition of tumour growth by aspirin and indomethacin
6. Alteration of tumour growth by aspirin and indomethacin: Studies with two transplantable tumours in mouse
7. Antiproliferative activity of anti-inflammatory drugs in two mammalian cell culture lines
8. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
9. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
10. Increased cyclo-oxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
11. Cell Pathways receive US patent for method of identifying drugs to selectively treat or prevent precancerous and cancerous lesions; patent describes novel method of action for Prevatac (exisulind) and other selective apoptotic antineoplastic drugs
12. Cell Pathways' European and Japanese patents allowed on method for identifying drugs that selectively trigger death of precancerous and cancerous cells
13. Inflammation and the mechanism of action of anti-inflammatory drugs
14. Mechanism of action of aspirin-like drugs
15. Anti-inflammatory drugs and their mechanism of action
16. Mechanism of action of nonsteroidal anti-inflammatory drugs
17. Clinical pharmacokinetics of sulindac. A dynamic old drug
18. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process
19. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
20. Profile of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors
21. The role of prostaglandins in the regulation of cell proliferation
22. The role of prostaglandins in the regulation of cell proliferation
23. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac
24. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
25. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
26. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis
27. Colon cancer prevention by NSAIDs: What is the mechanism of action?
28. Effects of long-term sulindac therapy on colonic polyposis
29. 2 and angiogenesis
30. Effects of prostaglandin synthesis inhibitors on tumor growth and vascularization. Experimental studies in the rat
31. Inhibitory effect of theobromine on induction of angiogenesis and VEGF mRNA expression in v-raf transfectants of human urothelial cells HCV-29
32. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
33. Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin
34. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
35. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines
36. Sulindac inhibits activation of the NF-κB pathway
37. Sulindac sulfide inhibits Ras signaling
38. Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation
39. Dissection of TNF receptor effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death
40. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
41. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
42. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation and attenuated β-catenin
43. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1
44. Apoptotic signalling cascade in photosensitized human epidermal carcinoma A431 cells: Involvement of singlet oxygen, c-Jun N-terminal kinase, caspase-3 and p21-activated kinase 2
45. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells
46. Antiproliferative effect of nosteroidal antiinflammatory drugs against human colon cancer cells
47. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
48. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines
49. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors
50. Effect of indomethacin on intestinal tumors induced in rats by acetate derivative of dimethylnitrosamine
51. A protective effect of sulindac against chemically-induced primary colonic tumours in mice
52. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat
53. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
54. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
55. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
56. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone)
57. Sulindac for polyposis of the colon
58. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
59. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: Evaluation of predictive factors
60. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis
61. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth
62. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis
63. Cell Pathways' Aptosyn - Exisulind - Inhibits the rise in PSA levels in prostate cancer patients following radical prostatectomy
64. Drug development pipeline: CP-461 and exisulind
65. Preclinical research demonstrates broad anticancer activity of Cell Pathways' SAANDs compounds
66. Cell Pathways advances clinical development of second-generation SAANDs drug, CP461
67. Novel Cell Pathways anticancer drug achieves high blood levels and good tolerability in phase la trial
68. A pharmacokinetic and safety study of a selective apoptotic antineoplastic drug (SAAND), CP461, in healthy volunteers
69. Cell Pathways files IND for new anticancer compound, CP461, and expands clinical trials of lead investigational drug, Prevatac `exisulind'
70. Cell Pathways Aptosyn and CP461 show synergy with Herceptin and Taxotere, as well as activity against breast cancers resistant to those drugs
71. CP-461 enhances the antitumor effects of paclitaxel in subcutaneously implanted human mammary tumor (MX-1) xenographs in nude mice
72. Preclinical studies show Cell Pathways' exisulind is synergistic with conventional chemopreventive and chemotherapeutic drugs
73. Antineoplastic effects of exisulind (Prevatac) and its analogs on leulemia and myeloma cell lines
74. Exisulind and CP-461 enhance the growth inhibitory effects of chemotherapeutic agents on human lung cancer cell lines; Research presented at European Cancer Conference details additive and synergistic effects of SAANDs compounds
75. European Society of Medical Oncology 25th Anniversary Meeting (Part II), Hamburg, Germany
76. Cell Pathways scientists describe mechanism by which SAANDs compounds trigger programmed death in cancerous and precancerous cells
77. New research demonstrates anti-angiogenic properties for SAANDs despite the presence of vascular growth stimulators
78. New research extends understanding of how SAANDs trigger suicide in cancerous and precancerous cells via multiple apoptosis pathways; Clinical cancer research publication further describes mechanism of action for a new class of anticancer drugs